NEWS HIGHLIGHTSMedia Articles Related to Oxsoralen Topical (Methoxsalen Topical)
Cure For Gray Hair And Vitiligo Found
Source: Dermatology News From Medical News Today [2013.05.05]
A modified pseudocatalase, a new compound that reverses oxidative stress may provide a cure for loss of skin or hair color, i.e. gray hair or vitiligo, researchers from the United Kingdom and Germany reported in The FASEB Journal. The need to use hair dyes to cover up a classic sign of aging - gray hair - may soon be a thing of the past...
Experimental Vitiligo Treatment Shows Promise in Mice
Source: MedicineNet Vitiligo Specialty [2013.02.28]
Title: Experimental Vitiligo Treatment Shows Promise in Mice
Category: Health News
Created: 2/27/2013 2:36:00 PM
Last Editorial Review: 2/28/2013 12:00:00 AM
Skin Cell Transplant May Offer New Hope to Vitiligo Patients
Source: MedicineNet Vitiligo Specialty [2012.06.25]
Title: Skin Cell Transplant May Offer New Hope to Vitiligo Patients
Category: Health News
Created: 6/22/2012 2:05:00 PM
Last Editorial Review: 6/25/2012 12:00:00 AM
Vitiligo
Source: MedicineNet Achalasia Specialty [2010.08.01]
Title: Vitiligo
Category: Diseases and Conditions
Created: 7/11/1999 5:59:00 AM
Last Editorial Review: 8/1/2010 12:00:00 AM
Published Studies Related to Oxsoralen Topical (Methoxsalen Topical)
An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. [2003.07]
We compared the characteristics of psoralen and ultraviolet A (PUVA) erythema in skin photosensitized by bath or oral methoxsalen in 20 subjects. Erythema was assessed visually and with a reflectance instrument at 24 h intervals for 7 days.
The time course of topical PUVA erythema following 15- and 5-minute methoxsalen immersion. [2003.03]
CONCLUSIONS: Methoxsalen-UV-A erythema exhibited a broad plateau between 96 and 144 hours, with most subjects at peak erythema at 120 hours. Reduction of methoxsalen immersion time significantly lowered the erythemal intensity. Minimum phototoxic dose reading at 72 hours underestimates the phototoxic effect of topical methoxsalen PUVA, and a change in the MPD assessment time should be considered.
Microemulsions for topical delivery of 8-methoxsalen. [2000.10.03]
8-Methoxsalen (8-MOP) and related furocumarins have been extensively used for the treatment of hyperproliferative skin diseases in association with long-wavelength UVA light. In order to develop alternative formulations for the topical administration of 8-MOP, microemulsions were evaluated as delivery vehicles...
Clinical Trials Related to Oxsoralen Topical (Methoxsalen Topical)
A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease [Recruiting]
The purpose of this study is to evaluate the safety and effectiveness of extracorporeal
photopheresis therapy when added to standard drug therapies administered to patients with
moderate to severe chronic graft-versus-host disease.
PUVA Maintenance Therapy in Mycosis Fungoides [Not yet recruiting]
The purpose of the study is to determine whether psoralen plus UVA (PUVA) photochemotherapy
maintenance treatment prolongs disease-free survival of cutaneous T cell lymphoma (mycosis
fungoides) patients.
Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis [Recruiting]
The purpose of this prospective, randomized, controlled, single-blinded investigation is to
study the efficacy, tolerability and safety of oral photochemotherapy (PUVA) combined with
acitretin versus oral PUVA combined with systemic fumaric acid esters (FAE) in patients with
pustular palmoplantar psoriasis.
Patients will be randomized and allocated in concealed manner to one of the two treatment
arms: acitretin-PUVA or FAE-PUVA.
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART) [Recruiting]
The objectives of this clinical trial are to:
- Assess the safety of using extracorporeal photoimmune therapy with the photosensitizing
agent Uvadex in the treatment of HIV-1 infection;
- Evaluate the effects of this therapy on HIV-1 viral load by polymerase chain reaction
(PCR) analysis;
- Evaluate the effects of this therapy on CD4+, CD8+ cells and CD4/CD8 ratio;
- Evaluate the effects of this therapy on the patient's immune system, by skin reactivity
to a standard anergy panel.
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-Versus-Host Disease [Active, not recruiting]
The purpose of this study is to determine whether Extracorporeal Photopheresis with UVADEX
(ECP) prior to bone marrow or peripheral blood stem cell transplantation is effective in the
prevention of Graft-versus-Host Disease (GvHD).
|
